Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma

Blood

Volumn 124, Issue 12, 2014, Pages 1915-1925

  Venkata, Jagadish Kummetha ^a   An, Ningfei ^a   Stuart, Robert ^a   Costa, Luciano J ^a   Cai, Houjian ^b   Coker, Woodrow ^a   Song, Jin H ^c   Gibbs, Kiwana ^d   Matson, Terri ^d   Garrett Mayer, Elizabeth ^d   Wan, Zhuang ^d   Ogretmen, Besim ^c   Smith, Charles ^e,f   Kang, Yubin ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^f APOGEE BIOTECHNOLOGY CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 CHLOROPHENYL) N (4 PYRIDINYLMETHYL)ADAMANTANE 1 CARBOXAMIDE; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; CASPASE 3; MYC PROTEIN; PROTEIN BCL 2; PROTEIN MCL 1; SHORT HAIRPIN RNA; 3-(4-CHLOROPHENYL)-ADAMANTANE-1-CARBOXYLIC ACID (PYRIDIN-4-YLMETHYL)AMIDE; ADAMANTANE; ANTINEOPLASTIC AGENT; CASP3 PROTEIN, HUMAN; ENZYME INHIBITOR; MCL1 PROTEIN, HUMAN; MESSENGER RNA; MYC PROTEIN, HUMAN; PHOSPHOTRANSFERASE; PMAIP1 PROTEIN, HUMAN; PROTEASOME; PYRIDINE DERIVATIVE; RNA; SMALL INTERFERING RNA; SPHINGOSINE KINASE 2, HUMAN;

ANIMAL CELL; APOPTOSIS; ARTICLE; BONE MARROW; CELL PROLIFERATION; CELL SURVIVAL; DOWN REGULATION; DRUG EFFECT; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIPLE MYELOMA; MYELOMA; MYELOMA CELL; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; STROMA CELL; TUMOR GROWTH; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; GENETICS; KNOCKOUT MOUSE; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY; SCID MOUSE; TUMOR CELL LINE;

ADAMANTANE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; ENZYME INHIBITORS; HUMANS; MICE; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; MULTIPLE MYELOMA; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC; PYRIDINES; RNA, MESSENGER; RNA, NEOPLASM; RNA, SMALL INTERFERING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84907189574     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-03-559385     Document Type: Article

References (70)

1. Ghobrial IM, Laubach JP, Richardson PG. Plasma cell dyscrasias. In: Gregory SA and McCrae KR, ed. ASH-SAP: American Society of Hematology Self-Assessment Program: American Society of Hematology. 4th ed. 2010; 581-604.
2. Laubach J, Richardson P, Anderson K. Multiple myeloma. Annu Rev Med 2011; 62:249-264.
3. Furuya H, Shimizu Y, Kawamori T. Sphingolipids in cancer. Cancer Metastasis Rev. 2011; 30(3-4): 567-576.
4. Santos CR, Schulze A. Lipid metabolism in cancer. FEBS J 2012; 279(15):2610-2623.
5. Snider AJ, Orr Gandy KA, Obeid LM. Sphingosine kinase: Role in regulation of bioactive sphingolipid mediators in inflammation. Biochimie 2010; 92(6):707-715.
6. Nixon GF. Sphingolipids in inflammation: pathological implications and potential therapeutic targets. Br J Pharmacol 2009; 158(4):982-993.
7. Maceyka M, Milstien S, Spiegel S. Sphingosine-1-phosphate: the Swiss army knife of sphingolipid signaling. J Lipid Res. 2009; 50(Suppl): S272-S276.
8. Cowart LA. Sphingolipids: players in the pathology of metabolic disease. Trends Endocrinol Metab 2009; 20(1):34-42.
9. Saddoughi SA, Song P, Ogretmen B. Roles of bioactive sphingolipids in cancer biology and therapeutics. Subcell Biochem 2008; 49:413-440.
10. Billich A, Baumruker T. Sphingolipid metabolizing enzymes as novel therapeutic targets. Subcell Biochem 2008; 49:487-522.
11. Cuvillier O. Sphingosine in apoptosis signaling. Biochim Biophys Acta 2002; 1585(2-3):153-162.
12. Cuvillier O, Pirianov G, Kleuser B., et al. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature. 1996; 381(6585):800-803.
13. T PL. Wang HG. Editorial [hot topic: therapeutic targeting of the sphingolipid "biostat" in hematologic malignancies (guest editors: Thomas P. Loughran and Hong-Gang Wang)]. Anticancer Agents Med Chem. 2011; 11(9):780-781.
14. Ponnusamy S, Meyers-Needham M, Senkal C.E., et al. Sphingolipids and cancer: ceramide and sphingosine-1-phosphate in the regulation of cell death and drug resistance. Future Oncol 2010; 6(10):1603-1624.
15. Oskouian B, Saba JD. Cancer treatment strategies targeting sphingolipid metabolism. Adv Exp Med Biol 2010; 688:185-205.
16. Ekiz HA, Baran Y. Therapeutic applications of bioactive sphingolipids in hematological malignancies. Int J Cancer 2010; 127(7): 1497-1506.
17. Leong WI, Saba JD. S1P metabolism in cancer and other pathological conditions. Biochimie 2010; 92(6):716-723.
18. Ryland LK, Fox TE, Liu X, Loughran T.P., Kester M. Dysregulation of sphingolipid metabolism in cancer. Cancer Biol Ther 2011; 11(2):138-149.
19. Mathias S, Peña LA, Kolesnick RN. Signal transduction of stress via ceramide. Biochem J. 1998; 335(Pt 3):465-480.
20. Perry DK, Hannun YA. The role of ceramide in cell signaling. Biochim Biophys Acta. 1998; 1436(1-2): 233-243.
21. Perry DK, Kolesnick RN. Ceramide and sphingosine 1-phosphate in anti-cancer therapies. Cancer Treat Res 2003; 115:345-354.
22. Kolesnick R, Fuks Z. Radiation and ceramide-induced apoptosis. Oncogene 2003; 22(37): 5897-5906.
23. Olivera A, Spiegel S. Sphingosine kinase: a mediator of vital cellular functions. Prostaglandins 2001; 64(1-4):123-134.
24. Spiegel S, Milstien S. Sphingosine 1-phosphate, a key cell signaling molecule. J Biol Chem 2002; 277(29):25851-25854.
25. Yasui H, Hideshima T, Raje N., et al. FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance. Cancer Res 2005; 65(16):7478-7484.
26. Li QF, Wu CT, Guo Q, Wang H., Wang LS. Sphingosine 1-phosphate induces Mcl-1 upregulation and protects multiple myeloma cells against apoptosis. Biochem Biophys Res Commun 2008; 371(1):159-162.
27. Yabu T, Tomimoto H, Taguchi Y., Yamaoka S, Igarashi Y, Okazaki T. Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate. Blood 2005; 106(1):125-134.
28. García-Bernal D., Redondo-Muñoz J, Dios-Esponera A, et al. Sphingosine-1-phosphate activates chemokine-promoted myeloma cell adhesion and migration involving a4b1 integrin function. J Pathol 2013; 229(1):36-48.
29. Liang J, Nagahashi M, Kim E.Y., et al. Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. Cancer Cell 2013; 23(1):107-120.
30. Ponnusamy S, Selvam SP, Mehrotra S, et al. Communication between host organism and cancer cells is transduced by systemic sphingosine kinase 1/sphingosine 1-phosphate signalling to regulate tumour metastasis. EMBO Mol Med 2012; 4(8):761-775.
31. Li QF, Wu CT, Duan H.F., et al. Activation of sphingosine kinase mediates suppressive effect of interleukin-6 on human multiple myeloma cell apoptosis. Br J Haematol 2007; 138(5):632-639.
32. Strub GM, Maceyka M, Hait N.C., Milstien S., Spiegel S. Extracellular and intracellular actions of sphingosine-1-phosphate. Adv Exp Med Biol 2010; 688:141-155.
33. Pitman MR, Pitson SM. Inhibitors of the sphingosine kinase pathway as potential therapeutics. Curr Cancer Drug Targets 2010; 10(4):354-367.
34. Cuvillier O, Ader I, Bouquerel P., et al. Activation of sphingosine kinase-1 in cancer: implications for therapeutic targeting. Curr Mol Pharmacol 2010; 3(2):53-65.
35. Gangoiti P, Camacho L, Arana L., et al. Control of metabolism and signaling of simple bioactive sphingolipids: Implications in disease. Prog Lipid Res 2010; 49(4):316-334.
36. Burger R, Guenther A, Bakker F., et al. Gp130 and ras mediated signaling in human plasma cell line INA-6: a cytokine-regulated tumor model for plasmacytoma. Hematol J 2001; 2(1):42-53.
37. Burger R, Neipel F, Fleckenstein B., et al. Human herpesvirus type 8 interleukin-6 homologue is functionally active on human myeloma cells. Blood 1998; 91(6):1858-1863.
38. Lukacs RU, Memarzadeh S, Wu H., Witte ON. Bmi-1 is a crucial regulator of prostate stem cell self-renewal and malignant transformation. Cell Stem Cell 2010; 7(6):682-693.
39. Chng WJ, Kumar S, Vanwier S., et al. Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Res 2007; 67(7):2982-2989.
40. Tiedemann RE, Zhu YX, Schmidt J, et al. Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6. Blood 2010; 115(8):1594-1604.
41. French KJ, Zhuang Y, Maines L.W., et al. Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2. J Pharmacol Exp Ther 2010; 333(1): 129-139.
42. Derenne S, Monia B, Dean N.M., et al. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood 2002; 100(1):194-199.
43. Zhang B, Gojo I, Fenton RG. Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood 2002; 99(6):1885-1893.
44. Wuillème-Toumi S., Robillard N, Gomez P, et al. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia 2005; 19(7):1248-1252.
45. Morales AA, Gutman D, Lee K.P., Boise LH. BH3-only proteins Noxa, Bmf, and Bim are necessary for arsenic trioxide-induced cell death in myeloma. Blood 2008; 111(10):5152-5162.
46. Gomez-Bougie P, Wuillème-Toumi S, Ménoret E, et al. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. Cancer Res 2007; 67(11): 5418-5424.
47. Alves NL, Derks IA, Berk E, Spijker R., van Lier RA, Eldering E. The Noxa/Mcl-1 axis regulates susceptibility to apoptosis under glucose limitation in dividing T cells. Immunity 2006; 24(6):703-716.
48. Shou Y, Martelli ML, Gabrea A, et al. Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc Natl Acad Sci USA 2000; 97(1):228-233.
49. Kuehl WM, Bergsagel PL. MYC addiction: a potential therapeutic target in MM. Blood 2012; 120(12):2351-2352.
50. Pene F, Claessens YE, Muller O, et al. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene 2002; 21(43):6587-6597.
51. Gao P, Peterson YK, Smith R.A., Smith CD. Characterization of isoenzyme-selective inhibitors of human sphingosine kinases. PLoS ONE. 2012; 7(9):e44543.
52. Antoon JW, Meacham WD, Bratton M.R., et al. Pharmacological inhibition of sphingosine kinase isoforms alters estrogen receptor signaling in human breast cancer. J Mol Endocrinol 2011; 46(3):205-216.
53. Antoon JW, White MD, Meacham W.D., et al. Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640. Endocrinology 2010; 151(11):5124-5135.
54. Antoon JW, White MD, Slaughter E.M., et al. Targeting NF-κB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2. Cancer Biol Ther 2011; 11(7):678-689.
55. Beljanski V, Knaak C, Smith CD. A novel sphingosine kinase inhibitor induces autophagy in tumor cells. J Pharmacol Exp Ther 2010; 333(2): 454-464.
56. Beljanski V, Knaak C, Zhuang Y., Smith CD. Combined anticancer effects of sphingosine kinase inhibitors and sorafenib. Invest New Drugs 2010; 29(6):1132-1142.
57. Beljanski V, Lewis CS, Smith CD. Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts. Cancer Biol Ther 2011; 11(5):524-534.
58. Chumanevich AA, Poudyal D, Cui X., et al. Suppression of colitis-driven colon cancer in mice by a novel small molecule inhibitor of sphingosine kinase. Carcinogenesis 2010; 31(10):1787-1793.
59. Ader I, Brizuela L, Bouquerel P., Malavaud B, Cuvillier O. Sphingosine kinase 1: a new modulator of hypoxia inducible factor 1alpha during hypoxia in human cancer cells. Cancer Res 2008; 68(20):8635-8642.
60. Ahmad M, Long JS, Pyne N.J., Pyne S. The effect of hypoxia on lipid phosphate receptor and sphingosine kinase expression and mitogen-activated protein kinase signaling in human pulmonary smooth muscle cells. Prostaglandins Other Lipid Mediat 2006; 79(3-4):278-286.
61. Anelli V, Gault CR, Cheng A.B., Obeid LM. Sphingosine kinase 1 is up-regulated during hypoxia in U87MG glioma cells. Role of hypoxia-inducible factors 1 and 2. J Biol Chem 2008; 283(6):3365-3375.
62. Schwalm S, Döll F, Römer I, Bubnova S., Pfeilschifter J, Huwiler A. Sphingosine kinase-1 is a hypoxia-regulated gene that stimulates migration of human endothelial cells. Biochem Biophys Res Commun. 2008; 368(4):1020-1025.
63. Le Scolan E, Pchejetski D, Banno Y., et al. Overexpression of sphingosine kinase 1 is an oncogenic event in erythroleukemic progression. Blood 2005; 106(5):1808-1816.
64. Xia P, Gamble JR, Wang L, et al. An oncogenic role of sphingosine kinase. Curr Biol 2000; 10(23): 1527-1530.
65. Maceyka M, Sankala H, Hait N.C., et al. SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism. J Biol Chem 2005; 280(44):37118-37129.
66. Okada T, Ding G, Sonoda H., et al. Involvement of N-terminal-extended form of sphingosine kinase 2 in serum-dependent regulation of cell proliferation and apoptosis. J Biol Chem 2005; 280(43): 36318-36325.
67. Döll F, Pfeilschifter J, Huwiler A. The epidermal growth factor stimulates sphingosine kinase-1 expression and activity in the human mammary carcinoma cell line MCF7. Biochim Biophys Acta 2005; 1738(1-3):72-81.
68. Hait NC, Sarkar S, Le Stunff H, et al. Role of sphingosine kinase 2 in cell migration toward epidermal growth factor. J Biol Chem 2005; 280(33):29462-29469.
69. Van Brocklyn JR, Jackson CA, Pearl D.K., Kotur MS, Snyder PJ, Prior TW. Sphingosine kinase-1 expression correlates with poor survival of patients with glioblastoma multiforme: roles of sphingosine kinase isoforms in growth of glioblastoma cell lines. J Neuropathol Exp Neurol 2005; 64(8):695-705.
70. Weigert A, Schiffmann S, Sekar D., et al. Sphingosine kinase 2 deficient tumor xenografts show impaired growth and fail to polarize macrophages towards an anti-inflammatory phenotype. Int J Cancer 2009; 125(9):2114-2121.